Near Death Experience (NDE) and Migraine

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02854930

Enrollment

100

Registered

2016-08-04

Start date

2017-01-31

Completion date

2018-03-31

Last updated

2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine, Near Death Experience

Keywords

Clinical death, state of consciousness

Brief summary

Migraine is a common disabling primary headache disorder. Epidemiological studies have documented its high prevalence and high socio-economic and personal impacts. Migraine affects more than 20% of the French population. However, the physiopathology of migraine is always partially known. Cortical spreading depression (CSD) is the widely accepted as the electrophysiologic substrate of migraine aura. CSD is a slowly propagating wave of transient neuronal and glial depolarization. The near death experience (NDE) is a rare, but well known phenomenon. NDE are profound psychic experiences commonly occuring in life-threatening conditions. Among the neurological hypotheses, epilepsy, temporal lobe disorders , REM-sleep intrusion have been discussed. However, the role of DCE has never been discussed. The goals of this study are : to see if there is an epidemiological link between NDE and migraine/ to specify if NDE was followed by a migrainous headache.

Interventions

OTHERquestioning

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subject who experienced an NDE defined by the occurrence, when the subject is in a state of clinical death or a particular state of consciousness of a following event: body output experience, disembodiment, for a tunnel and / or light; * Topic recorded in the EMI database (Dr. Postel, National Center for Education, Research and Information on the conscience; * Topic agreeing to participate in the study.

Exclusion criteria

* Patient mental condition or disorder or psychiatric history or any other factor limiting the ability to participate in an informed manner and compliant to the study; * Other than obtained Participation Agreement.

Design outcomes

Primary

Measure	Time frame
Quality of life	one day

Countries

France

Contacts

Primary ContactAnne Donnet

drci@ap-hm.fr0491382747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026